Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Occupational Impact and Chemotherapy-Induced Peripheral Neuropathies (CIPN) (IMPOCNPIC)

12 listopada 2026 zaktualizowane przez: Centre Hospitalier Intercommunal Creteil

Occupational Impact and Chemotherapy-Induced Peripheral Neuropathies (CIPN): A Descriptive Study of Occupational Issues to Guide Occupational Therapy Intervention

Advances in cancer treatment have increased the number of patients living with long-term treatment-related consequences. Among these, chemotherapy-induced peripheral neuropathy (CIPN) is common and can significantly affect patients' quality of life and daily activities. Despite its impact, CIPN remains difficult to manage, and patients often receive insufficient support regarding its functional and occupational consequences.

Occupational therapy remains underutilised in oncology, despite its potential to help patients maintain or regain independence in meaningful daily activities. Collaboration between Advanced Practice Nurses and occupational therapists could improve the identification and management of occupational difficulties associated with CIPN.

The aim of this study is to describe the occupations affected by CIPN using the Canadian Occupational Performance Measure (COPM). The findings will help identify patients' occupational needs and guide future occupational therapy interventions.

Przegląd badań

Status

Rekrutacyjny

Warunki

Szczegółowy opis

In 2023, 433,136 new cancer cases were reported in France, accounting for 8.1 million hospital admissions. Thanks to advances in cancer treatment, the number of patients living with long-term consequences of cancer or its treatment is steadily increasing.

Cancer control policies in France have been based on successive Cancer Plans, followed by the adoption of the 2021-2030 Ten-Year Cancer Control Strategy. This strategy is structured around four priority areas, including the second: "Reducing long-term consequences and improving quality of life." Indeed, two out of three people experience lasting effects five years after a cancer diagnosis. This priority aims to promote research to reduce long-term consequences and improve patients' quality of life, as well as to prevent, detect and manage the effects associated with the disease and its treatments. In particular, findings from the VICAN 5 study show that 63.5% of cancer survivors continue to experience disease- or treatment-related consequences five years after diagnosis. Among these patients, 35.3% reported neuropathic pain, which negatively affects their quality of life and daily activities. Chemotherapy-induced peripheral neuropathy (CIPN) is common and remains difficult to manage because of its limited response to pharmacological treatments.

Current literature highlights a lack of support and care for patients experiencing CIPN, as well as insufficient knowledge regarding its impact on their daily activities and occupations.

The cancer care pathway can be divided into three main stages: diagnosis disclosure, treatment, and post-cancer care. Advanced Practice Nurses (APNs) can intervene at different stages of this pathway. They play a major role in long-term follow-up, particularly in identifying and monitoring treatment-related side effects and long-term consequences. However, their role, which primarily focuses on screening and monitoring, does not allow them to provide specific interventions aimed at improving the management of CIPN-related difficulties.

Occupational therapy aims to help individuals regain or maintain their independence in carrying out everyday activities. It offers a wide range of interventions but remains underutilised in oncology, for several reasons, including limited awareness of the profession, insufficient knowledge of its potential benefits, and difficulties accessing occupational therapy services.

In the management of CIPN, collaboration between Advanced Practice Nurses and occupational therapists could help establish effective care pathways, combine their respective expertise and promote patients' engagement in activities affected by CIPN.

The objective of this study is to describe the occupations (activities or groups of activities performed regularly and considered meaningful and valuable by individuals) affected by CIPN, using the Canadian Occupational Performance Measure (COPM).

Occupational performance is defined as an individual's ability to perform meaningful occupations adequately, efficiently and to their own satisfaction.

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

50

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

      • Créteil, Francja, 94000
        • Rekrutacyjny
        • Centre Hospitalier Intercommunal de Créteil
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

Adult patients with chemotherapy-induced peripheral neuropathy, grade 2 or 3 according to CTCAE: caused by paclitaxel in cases of breast cancer or by oxaliplatin in cases of colorectal cancer.

Patients must be able to carry on a conversation in French.

Opis

Inclusion Criteria:

  • Patient treated for breast cancer or colorectal cancer, who has not previously received paclitaxel or oxaliplatin.
  • Patient with grade 2 or 3 peripheral neuropathy, according to the CTCAE criteria, occurring during their treatment.
  • Patient able to communicate in French.
  • Patient aged 18 years or older

Exclusion Criteria:

  • History of neuropathy prior to treatment.
  • Refusal to participate in the study.
  • Protected persons (pregnant or breastfeeding women, individuals under guardianship or curatorship, minors, individuals deprived of their liberty, or individuals unable to provide informed consent).

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Modele obserwacyjne: CASE_ONLY
  • Perspektywy czasowe: PROSPECTIVE

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Description of the occupational issues identified as priorities by patients
Ramy czasowe: 3 months

Describe the occupational issues identified as priorities by patients based on the categories and subcategories of occupations defined by the MCRO

3 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Patient verbatim
Ramy czasowe: 3 months

Patient verbatim statements regarding their priority occupational issues, grouped according to the MCRO categories and subcategories

3 months
Performance and satisfaction scores
Ramy czasowe: 3 months

Performance and satisfaction scores obtained across each category and subcategory of the MCRO

3 months
Number and percentages of priority problematic occupations
Ramy czasowe: 3 months

Number and percentages of priority problematic occupations, coded according to the categories and subcategories of the MCRO, based on the two types of treatment received.

3 months
Number and percentages of priority adverse events
Ramy czasowe: 3 months

Number and percentages of priority adverse events, coded according to the categories and subcategories of the MCRO, based on the two CTCAE grading scales

3 months
Average time to onset of NPICs by treatment received
Ramy czasowe: 3 months

Average time to onset of NPICs by treatment received. The time to onset of NPICs is defined as the interval (in days) between the start date of treatment and the date of NPIC diagnosis

3 months

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

9 listopada 2026

Zakończenie podstawowe (Szacowany)

9 lutego 2027

Ukończenie studiów (Szacowany)

9 lutego 2027

Daty rejestracji na studia

Pierwszy przesłany

12 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

12 listopada 2026

Pierwszy wysłany (Rzeczywisty)

19 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

19 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

12 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • IMPOC NPIC
  • IDRCB: 2026-A01727-44 (Inny identyfikator: Centre Hospitalier Intercommunal Creteil)

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .